摘要
霍奇金淋巴瘤（HL）是起源于淋巴造血组织的恶性肿瘤，其典型的病理特征是R—S细胞存在于不同类型的炎症细胞背景中。HL发病率约占淋巴瘤总数的10％，是治疗效果较好、治愈率较高的恶性肿瘤之一，治愈率可达80％～90％。但仍有约10％的HL患者难治或复发，成为研究的重点。近年来随着HL分子生物学及放化疗、靶向药物等治疗新技术的应用，HL的发病机制、预后标志及治疗方面的研究均取得了新进展。
Hodgkin lymphoma （HL） is a type of malignant tumor originating from the lymphoid hematopoietie tissues. Its typical pathological feature is the existence of R-S cells in the background of the different types of inflammatory cells. HL represents about 10 % of the total lymphoma and has good treatment outcome with 80 %-90 % cure rate. However, there are still about 10 % of patients with refractory or relapsed lymphoma, which has become research focus of HL. In recent years, along with the application of molecular biology techniques, radiotherapy, chemotherapy and targeted therapy in treating HL, significant progress has been made in pathogenesis, prognosis and treatment of HL.
出处
《白血病．淋巴瘤》
CAS
2014年第5期308-311,共4页
Journal of Leukemia & Lymphoma
关键词
霍奇金淋巴瘤
发病机制
预后
治疗
Hodgkin lymphoma
Pathogenesis
Prognosis
Treatment
